“An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation’s two premier cancer research organizations. The presidents of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) organized the session focused on the COX-2 enzyme and cancer treatment Monday afternoon — April 20, 2:30-4:30 p.m., in rooms 205-207 of the Colorado Convention Center — at the AACR’s 100th Annual Meeting 2009 in Denver. A similar symposium on new molecular targets will be conducted at ASCO’s annual meeting in May 29- June 2 in Orlando. COX-2 is best known as a target for preventing dangerous polyps that lead to colorectal cancer, but it is also advancing as a target for treatment of many solid tumors. …“
“Leading cancer organizations team up on tumor-promoting protein – AACR and ASCO begin joint symposia at annual meetings with focus on COX-2
An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation’s two premier cancer research organizations.
The presidents of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) organized the session focused on the COX-2 enzyme and cancer treatment Monday afternoon — April 20, 2:30-4:30 p.m., in rooms 205-207 of the Colorado Convention Center — at the AACR’s 100th Annual Meeting 2009 in Denver. A similar symposium on new molecular targets will be conducted at ASCO’s annual meeting in May 29- June 2 in Orlando.
‘Our symposium is timely because we are starting to see data from Phase II and Phase III clinical trials about COX-2 inhibition following post-surgical chemotherapy in colon cancer patients,’ said Raymond DuBois, M.D., Ph.D., president of AACR and provost and executive vice president at The University of Texas M. D. Anderson Cancer Center.
‘There’s been a great deal of preclinical and translational research addressing COX-2 overexpression in tumors and its role in cancer growth and survival. In prevention, inhibiting this enzyme reduces the number of high-risk precancerous polyps by 66 percent,’ DuBois said. ‘The time is ripe to combine basic science and clinical expertise to advance the therapeutic potential of this approach.’
‘The development of targeted therapies for cancer prevention and treatment requires the close collaboration and combined resources of basic scientists and clinical investigators,’ Schilsky said. ‘The success of targeted therapy for cancer depends first and foremost on a comprehensive understanding of the biology of the drug target coupled with a robust assay to assess target inhibition and a drug that hits the target. With these ingredients in place, clinical trials can be designed to assess the impact of treatment in the population most likely to benefit.’
‘The AACR/ASCO Symposium illustrates these core principles and demonstrates that continued progress against cancer requires the partnership of all investigators and practitioners represented by these two great organizations,’ Schilsky said.
The idea for joint symposia at each organization’s annual meeting has been discussed for years and was advanced by immediate past presidents William Hait, M.D., Ph.D., of AACR and Nancy Davidson, M.D., of ASCO.
DuBois and Schilsky co-chair the symposium. Scheduled presentations are:
- COX-2 and Cancer Biology by DuBois, who discovered the enzyme’s overexpression in tumors.
- Overview of COX-2 as a Target for Cancer Treatment, by Schilsky.
- COX-2 as a Target for Prevention and Treatment of Colorectal Cancer by Andrew Chan, M.D., of Massachusetts General Hospital.
- Early Epigenetic and Genetic Events in Carcinogenesis by Thea D. Tlsty, Ph.D., of the University of California School of Medicine, San Francisco.
- A Mouse Model for COX-2 Driven Pancreatitis and Pancreatic Ductal Carcinoma by Susan Fischer, Ph.D. of M. D. Anderson Cancer Center Science Park – Research Division, Smithville, Texas.”
* * *
AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. ASCO is the world’s leading professional organization representing physicians who care for people with cancer. Many scientists and physicians are members of both organizations.”
Source: Leading Cancer Organizations Team Up on Tumor-Promoting Protein – AACR and ASCO begin joint symposia at annual meetings with focus on COX-2, M.D. Anderson News Release, The University of Texas M.D. Anderson Cancer Center, April 17, 2009.
Comment: The relationship between ovarian cancer and COX-2 remains unclear. Some in vitro and in vivo studies make a connection between ovarian cancer and COX-2, while others suggest that COX-1 is more relevant to current ovarian cancer research. It is an area that warrants further investigation.
Recent Studies Re Ovarian Cancer and COX-2:
- Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J, Gong H, Cai Y. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest. 2008 Oct;26(8):822-9. PubMed PMID: 18798061.
- Li W, Zhang HH, Xu RJ, Zhuo GC, Hu YQ, Li J. Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med Oncol. 2008;25(2):172-7. Epub 2007 Oct 6. PubMed PMID: 18488158.
- Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A, Patsouris E. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204(4):241-9. Epub 2008 Jan 2. PubMed PMID: 18171606.
- European Cancer Conference. Mutation Of The COX2 Gene Can Double Or Triple A Woman’s Risk Of Ovarian Cancer. ScienceDaily 27 September 2007. 19 April 2009 <http://www.sciencedaily.com /releases/2007/09/070925095320.htm>.
- Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer. 2007 Aug 15;110(4):791-800. PubMed PMID: 17582802.
- Cao DY, Shen K, Yang JX, Guan J. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis]. Zhonghua Yi Xue Za Zhi. 2007 Jul 3;87(25):1738-41. Chinese. PubMed PMID: 17919376.
- Barnes AP, Miller BE, Kucera GL. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol. 2007 Feb;104(2):443-50. Epub 2006 Sep 22. PubMed PMID: 16996114.
- Xin B, Yokoyama Y, Shigeto T, Mizunuma H. Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol Oncol Res. 2007;13(4):365-9. Epub 2007 Dec 25. PubMed PMID: 18158574.
- Niesporek S, Weichert W, Sinn B, Röske A, Noske A, Buckendahl AC, Wirtz R, Sehouli J, Koensgen D, Dietel M, Denkert C. [NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]. Verh Dtsch Ges Pathol. 2007;91:243-9. German. PubMed PMID: 18314621.
- Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL. [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. Chinese. PubMed PMID: 17037745.
- Vital-Reyes V, Rodríguez-Burford C, Chhieng DC, Oelschlager DK, Reyes-Fuentes A, Barnes M, Grizzle WE. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med Res. 2006 Aug;37(6):689-95. PubMed PMID: 16824926.
- Ferrandina G, Ranelletti FO, Martinelli E, Paglia A, Zannoni GF, Scambia G. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer. 2006 Jul 11;6:182. PubMed PMID: 16831230; PubMed Central PMCID: PMC1534059.
- Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006 Mar 1;66(5):2527-31. PubMed PMID: 16510568.